Filing Flows › BioMarin Pharmaceutical (BMRN) › Free cash flow
BioMarin Pharmaceutical (BMRN) free cash flow by quarter
BioMarin Pharmaceutical's free cash flow was $160M in Q3 2026 (third quarter 2026), +15% from Q2 2026. Over the last 7 quarters it ranged from $58.9M (Q4 2025) to $340M (Q3 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $160M | +15% | -53% |
| Q2 2026 | $139M | -30% | -17% |
| Q1 2026 | $200M | +239% | +27% |
| Q4 2025 | $58.9M | -83% | — |
| Q3 2025 | $340M | +102% | — |
| Q2 2025 | $168M | +7% | — |
| Q1 2025 | $158M | — | — |
Q3 2026 at a glance
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
Questions
What is BioMarin Pharmaceutical's free cash flow?
BioMarin Pharmaceutical's free cash flow was $160M in Q3 2026 (third quarter 2026), +15% from Q2 2026.
How has BioMarin Pharmaceutical's free cash flow changed?
Over the last 7 quarters it ranged from $58.9M (Q4 2025) to $340M (Q3 2025).
Q3 2026 results → · How BioMarin Pharmaceutical makes money →